Login / Signup

Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.

Adrienne D CoxJenny P Y TingChanning J Der
Published in: Cancer discovery (2023)
In this issue, Hattori and colleagues capitalized on targeted small-molecule covalent inhibitors of one KRAS mutant with a G12C substitution and of other oncoproteins to create drug-peptide conjugates that serve as cancer neoantigens that prompt an immune response to oncogene-mutant cancer cells. This immunotherapy strategy can serve as an effective approach to overcome the treatment-induced resistance that limits the effectiveness of essentially all small molecule-based targeted anticancer drugs. See related article by Hattori et al., p. 132 (9).
Keyphrases
  • small molecule
  • cancer therapy
  • randomized controlled trial
  • protein protein
  • systematic review
  • drug induced
  • oxidative stress
  • high glucose
  • drug delivery
  • diabetic rats
  • endothelial cells